B Cells Regulate Macrophage Phenotype and Response to Chemotherapy in Squamous Carcinomas

Nesrine I. Affara,1,10 Brian Ruffell,1,5,8,10 Terry R. Medler,5 Andrew J. Gunderson,5 Magnus Johansson,1 Sophia Bornstein,7 Emily Bergsland,2,4 Martin Steinhoff,3 Yijin Li,9 Qian Gong,9 Yan Ma,9 Jane F. Wiesen,1,5 Melissa H. Wong,5,6,8 Molly Kulesz-Martin,5,6,8 Bryan Irving,9,11 and Lisa M. Coussens1,4,5,8,*

1Department of Pathology
2Department of Medicine
3Department of Dermatology
4Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco, San Francisco, CA 94143, USA
5Department of Cell and Developmental Biology
6Department of Dermatology
7Department of Radiation Medicine
8Knight Cancer Institute
Oregon Health and Science University, Portland, OR 97239, USA
9Genentech, South San Francisco, CA 94080, USA
10Co-first author
11Present address: CytomX Therapeutics, South San Francisco, CA 94080, USA
*Correspondence: coussenl@ohsu.edu
http://dx.doi.org/10.1016/j.ccr.2014.04.026

SUMMARY

B cells foster squamous cell carcinoma (SCC) development through deposition of immunoglobulin-containing immune complexes in premalignant tissue and Fcγ receptor-dependent activation of myeloid cells. Because human SCCs of the vulva and head and neck exhibited hallmarks of B cell infiltration, we examined B cell-deficient mice and found reduced support for SCC growth. Although ineffective as a single agent, treatment of mice bearing preexisting SCCs with B cell-depleting αCD20 monoclonal antibodies improved response to platinum- and Taxol-based chemotherapy. Improved chemoresponsiveness was dependent on altered chemokine expression by macrophages that promoted tumor infiltration of activated CD8+ lymphocytes via CCR5-dependent mechanisms. These data reveal that B cells, and the downstream myeloid-based pathways they regulate, represent tractable targets for anticancer therapy in select tumors.

INTRODUCTION

As the central component of humoral immunity, B lymphocytes function in immunoglobulin (Ig) production, antigen presentation, and secretion of proinflammatory cytokines. Although critical for combating pathogens and aiding tissue healing, population-based studies have revealed increased systemic humoral immune responses, including increased deposition of Ig into tissues, in individuals afflicted with some chronic inflammatory disorders associated with increased cancer risk. Cancer patients often develop antibodies to tumor-associated antigens; however, production of these antibodies does not necessarily confer protection, but instead often correlates with poor prognosis and decreased survival for several human cancer types. Population-based and experimental studies indicate that antitumor antibodies can facilitate tumor growth by promoting protumor immune responses and, in general, protecting malignant cells from cytotoxic T cell (CTL)-mediated killing (Gunderson and...
B Cells as a Therapeutic Target in SCC

Please cite this article in press as: Affara et al., B Cells Regulate Macrophage Phenotype and Response to Chemotherapy in Squamous Carcinomas, Cancer Cell (2014), http://dx.doi.org/10.1016/j.ccr.2014.04.026

(legend on next page)
Cancer Cell

B Cells as a Therapeutic Target in SCC

Coussens, 2013; Tan and Coussens, 2007), thus supporting a role for B cells and humoral immunity in fostering cancer development. Support for a protumor role for B cells is further provided by the realization that growth of some subcutaneous solid tumors is retarded in syngeneic B cell-deficient mice, associated with enhanced local expression of T helper (Th) 1 cytokines and increased infiltration of tumors by CTLs (Qin et al., 1998; Shah et al., 2005; Tadmor et al., 2011).

Using a transgenic mouse model of de novo squamous cell carcinoma (SCC) development (Coussens et al., 1996), we reported that B cells and humoral immunity foster SCC development by activating Fcγ receptors (FcγRs) on resident and recruited myeloid cells (Andreu et al., 2010; de Visser et al., 2005). Rather than infiltrating premalignant skin, Ig-secreting B cells exert distal effects on neoplastic tissue via production of circulating immune complexes (CICs) that accumulate in premalignant tissue (Andreu et al., 2010; de Visser et al., 2005). Following CIC engagement of activating-type I and activating-type III FcγRs, tumor progression is fostered through activation of proangiogenic, tissue remodeling, and prosurvival pathways in resident and recruited myeloid cells, in particular, macrophages and mast cells (Andreu et al., 2010). Based on these data, we hypothesized that B cells, and the downstream myeloid-based pathways they regulate, represented tractable targets for combinatorial therapy in SCC. We therefore examined the preclinical efficacy of a B cell-depleting \( \alpha \)CD20 monoclonal antibody (mAb) as an anticancer monotherapy, and in combination with chemotherapy (CTX).

RESULTS

B Cells in Human Solid Tumors

Unlike squamous carcinoma development in mice wherein premalignant and malignant tissues are poorly infiltrated by B cells (Andreu et al., 2010; de Visser et al., 2005; Schioppa et al., 2011), formation of tertiary/ectopic lymphoid structures containing B cells has been described for several malignant neoplasms, including breast, cervical, ovarian, and non-small-cell lung cancer (Kobayashi et al., 2002; Nelson, 2010). Based upon these data, we hypothesized that ectopic production of either Ig or CD20 mRNA might signify human cancers wherein the humoral immune response fosters neoplastic progression or tumor growth, and thus identify carcinomas potentially amenable to B cell-targeted therapies.

To address this, we queried cDNA microarray data on a panel of human tumors from the BioExpress System and assessed CD20 (MS4A1) and Ig (IGHG1, IGHG2, IGHV4-31, IGHM) mRNA expression relative to corresponding normal tissue. Multiple tumor types displayed increased CD20 or Ig expression as compared to nonmalignant tissue counterparts, but vulva SCCs and head and neck squamous cell carcinomas (HNSCCs) exhibited the greatest increase in CD20 and Ig mRNA expression, respectively (Figures 1A and 1B and Figure S1A available online), consistent with increased presence of CD20+ B cells in skin, vulva, and HNSCC as revealed by immunodetection (Figures 1C and 1D). Several Ig and Fcγ mRNAs were also found to be differentially expressed in HNSCC tumors relative to normal mucosa based on evaluation of a previously published data set (Ginos et al., 2004) using Oncomine (Rhodes et al., 2004) (Figure S1B). Notably, etiology for both vulva and HNSCCs is in part linked to human papillomavirus (HPV), with increasing incidence of carcinomas in both reflecting higher rates of HPV infection (Chaturvedi, 2010; Chaturvedi et al., 2011).

We have previously established that progression to carcinoma in a murine model of HPV16-induced SCC development (i.e., human keratin 14 (K14)-HPV16 mice) is dependent on binding of Igs to activating FcγRs on infiltrating myeloid cells (Andreu et al., 2010). Importantly, K14-HPV16 mice are not tolerant to HPV oncoproteins (Andreu et al., 2010; Daniel et al., 2005), reflecting a similar scenario in HPV-positive oropharyngeal cancer wherein HPV-specific peripheral blood CD8+ T cells have been described previously (Albers et al., 2005; Wansom et al., 2010). We therefore sought to evaluate the therapeutic efficacy of B cell depletion (i.e., \( \alpha \)CD20 mAbs) or inhibition of Fcγ signaling via a selective spleen tyrosine kinase (Syk) inhibitor (i.e., fostamatinib/R788) (Braselmann et al., 2006; Colonna et al., 2010) in either slowing or blocking progression of premalignant hyperplasia to dysplasia/carcinoma in situ.

Prevention of Premalignant Dysplasia by B Cell Depletion or Syk Kinase Inhibition

B cells, including mature B cells and plasma cells, accumulate in lymphoid organs of K14-HPV16 mice when neoplastic skin is at an early premalignant stage (Figures S2A–S2G). Accordingly, we conducted a prevention trial treating K14-HPV16 mice, starting at 1 month of age, with \( \alpha \)CD20 mAbs to effectively deplete B cells, as well as with the potent Syk inhibitor fostamatinib/R788, starting at 1 month of age, when neoplastic skin exhibited a low-grade hyperplastic state throughout, and continuing to 4 months of age when neoplastic skin instead contained focal areas of low/high-grade dysplasia (Figure 2A). R788 is an orally bioavailable small molecule with potent Syk kinase inhibitory activity, whose active metabolite (R406) binds the ATP binding pocket of Syk and inhibits its kinase activity as an ATP-competitive inhibitor (inhibitor constant \([K_i] > 30 \text{ nM}\) (Bahjat et al., 2008; Braselmann et al., 2006). Syk plays a key role in signaling.

Figure 1. CD20 and Ig mRNA Expression in Human Cancers

(A and B) Relative CD20 (A) and Ig (B) mRNA expression in a panel of human cancers. Data are represented as box-and-whisker plots depicting median fold change value compared to normal tissue, displaying the first and third quartiles at the end of each box, with the maximum and minimum at the ends of the whiskers. Number of human cancer tissue/number of normal tissue is shown for each organ. Shown are tissues with statistically significant differences between cancer tissue and control normal tissue, with significance determined via Wilcoxon rank-sum test, with \(*p < 0.05\), \( **p < 0.01\), and \( ***p < 0.001\).

(C) Representative histology of skin, vulva, and HNSCC in comparison to normal skin tissue. From left to right are hematoxylin and eosin staining (H&E) and immunohistochemistry (IHC) staining for CD45+ leukocytes and CD20+ B cells.

(D) Density of CD45+, CD20+, and CD8+ cells as determined by automated counting of IHC-stained sections. Ca, carcinoma.

See Figure S1 for complete analysis.
downstream of activating FcRs and B cell receptors (BCRs), and in several other cell lineages where activation leads to phosphor-
ylation of Syk and signal transduction via activation of phospho-
lipase Cγ and/or AKT. Notably, expression of mRNAs for both 
Syk and Bruton’s tyrosine kinase (BTK), another key signaling 
molecule downstream of FcRs and BCRs, was increased in 
HNSCC tumors relative to normal mucosa (Figure S1B). Phos-
phorylated BTK was also prominent in HNSCC tissue sections 
in CD20+ B cells and other stromal cells, as compared to normal 
mucosa (Figure 1C).

Figure 2. Inhibited Neoplastic Progression in K14-HPV16 Mice by Therapeutic αCD20 mAb or Fostamatinib

(A) Two stages of squamous carcinogenesis were evaluated: K14-HPV16 mice were enrolled at 1 month of age and received αCD20 or isotype control αRW at a 2-week interval until mice were 4 months of age (prevention), and B cell depletion or Syk inhibition was initiated at 3 months of age at a 2-week interval until mice were 6 months of age (intervention). Fostamatinib (R788), an orally bioavailable Syk kinase inhibitor, was administered through chow ad libitum at 2.0 g/kg/day to HPV16/FcRγ−/− and HPV16/FcRγ−/− mice at 1 month of age as compared to mice receiving control chow until 4 months of age.

(B) Percentages of ear skin (area) exhibiting dysplasia by 4 or 6 months of age following αCD20 mAb or fostamatinib administration. Values represent percentages of dysplastic lesions compared to whole ear skin per mouse with five to ten mice per experimental group. Results shown represent mean ± SEM. Representative H&E sections from the αCD20 mAb intervention study are shown to the right. Scale bars, 50 μm.

(C) Percentages of CD45+ immune cells in single-cell suspensions of skin as assessed by flow cytometry. Results shown represent mean ± SEM.

(D) Immune cell lineage analysis by flow cytometry as percentages of total CD45+ leukocyte infiltrates in ear tissue.

(E) Angiogenic vasculature in skin of cohorts as evaluated by CD31/platelet endothelial cell adhesion molecule-1 IHC. Values represent average of five high-power fields of view per mouse.

(F) Keratinocyte proliferation in skin of mice cohorts as assessed by automated counting of BrdU-positive keratinocytes per square millimeter of premalignant tissue. Data reflect three or more mice per group; statistical significance was determined via an unpaired t test, with *p < 0.05, **p < 0.01, and ***p < 0.001. See also Figure S2.
cells in peripheral blood and secondary lymphoid organs (Figures S2H–S2L), including a partial depletion of CD19+ CD1d+CD5+ B regulatory cells (Figure S2M), a subset of CD23+CD21hi marginal zone B cells (Figure S5B) implicated in repressing antimurin immunity in two-stage skin carcinogenesis (Schioppa et al., 2011), and in suppressing lymphoma (Horikawa et al., 2011). Critically, αCD20 mAb treatment reduced levels of circulating IgG (Figure S2N) and presence of autoantibodies against collagen I (Figure S2O); and consistent with a role of CIC deposition in skin of fostering neoplastic progression via FcγRs, treatment with either αCD20 mAb or fostamatinib effectively blocked progression to dysplasia in the prevention trial (Figure 2B).

Because Ig deposition into neoplastic skin of K14-HPV16 mice becomes pronounced between 2 and 3 months of age, we also conducted an intervention trial where 3-month-old K14-HPV16 mice with high-grade hyperplasia/low-grade focal dysplasia were treated with αCD20 mAbs to 6 months of age, when neoplastic skin exhibited broadly dysplastic regions of focal high-grade dysplasia/carcinoma in situ (Figure 2A). In this setting as well, B cell depletion via αCD20 mAb as monotherapy blocked progression to dysplasia and significantly induced regression to a hyperplastic phenotype (Figure 2B).

Impaired progression to dysplasia in both trials was associated with significantly reduced infiltration of neoplastic skin by CD45+ leukocytes (Figure 2C), encompassing reduced recruitment of CD11b+Gr1+F4/80 CD11c– immature myeloid cells, mast cells, and Gr1+ cells, with increased infiltration by CD11b+ Gr1– F4/80+CD11c+ macrophages, and T cells (Figure 2D; Figures S2P–S2S), similar to results reported for K14-HPV16/B cell-deficient and K14-HPV16/FcRγ-deficient mice (Andreu et al., 2010). In addition to limiting mast cell infiltration, R406, the active metabolite of fostamatinib, significantly reduced release of interleukin-4 (IL-4), tumor necrosis factor α (TNF-α), IL-23, IL-9, and transforming growth factor β (TGF-β) from IgG-stimulated bone marrow-derived mast cells in ex vivo assays (Figure S2T).

Moreover, similar to results reported for K14-HPV16/B cell-deficient and K14-HPV16/FcRγ-deficient mice (Andreu et al., 2010), the reduced and altered infiltration by leukocytes in αCD20 mAb- and fostamatinib-treated K14-HPV16 mice was associated with decreased development of angiogenic vasculature (Figure 2E) that translated into diminished keratinocyte hyperproliferation (Figure 2F). Taken together, these data indicate that B cell depletion and Syk kinase inhibition may represent therapeutic opportunities for prevention and/or intervention in K14-HPV16-positive squamous neoplasms.

**B Cell-Deficient Mice Fail to Support Orthotopic SCC Tumor Growth**

Given the increased expression of Ig mRNA in human SCCs (Figure 1) and the efficacy of αCD20 mAb in restricting premalignant progression in K14-HPV16 transgenic mice (Figure 2), we next sought to evaluate the antitumor efficacy of B cell depletion as either monotherapy or in combination with CTX. For this, we used SCC cell lines derived from K14-HPV16 mice (Arbeit et al., 1996) harboring de novo grade I well-differentiated (WDSC1) or poorly differentiated SCCs (PDSC5 clone 6). Similar to our results in syngeneic FcRγ-deficient mice (Andreu et al., 2010), orthotopic SCC growth was significantly reduced in syngeneic B cell-deficient (JH–/–) mice (Figures 3A and 3B), characterized by increased presence of CD45+ leukocytes, decreased bromodeoxyuridine (BrdU)+positive keratinocytes, increased cleaved caspase-3-positive cells, and decreased tumor vascularization, along with increased presence of CD8+ T cells (Figure S3A).

**Neoadjuvant αCD20 mAb as Monotherapy and in Combination with CTX**

These findings provided a compelling rationale for assessing αCD20 mAb in a therapeutic setting. Thus, we evaluated αCD20 mAb for efficacy in blocking development of syngeneic SCCs, as compared to slowing or inducing regression of pre-existent syngeneic SCCs. Mice were administered αCD20 mAb either at the time of tumor cell implantation and again at 2-week intervals (day 0; every 14 days), or instead when orthotopic tumors reached ~50 mm3 (day 12), and then every 14 days (Figure 3C). Using this strategy, CD19+ B220+CD138– mature B cells were efficiently depleted from lymphoid organs (spleen and bone marrow) (Figure S3B), culminating in reduced presence of circulating IgG (Figure S3C). Whereas administration of αCD20 mAb concurrent with SCC implantation significantly slowed tumor growth to end-stage (Figure 3C; Figure S3D), accompanied by reduced development of angiogenic vasculature (Figure S3E), tumor growth was not significantly slowed when αCD20 mAb therapy was initiated after tumors were apparent (Figure 3C; Figures S3D and S3E), despite a significantly increased percentage of CD8+ T cells infiltrating tumors (Figure 3D; Figure S3E).

Based on the increased presence of CD8+ T cells in orthotopic SCCs of αCD20 mAb-treated mice, we reasoned that efficacy might be enhanced by combination treatment with CTX. Indeed, treatment of mice bearing preexistent SCCs with αCD20 mAb in combination with cisplatin (CDPP) resulted in tumor regression in all animals (Figure S4A), as compared to CDPP alone, which was without effect. However, mice treated with αCD20/CDPP exhibited a 50% survival rate, likely due to cumulative impairment of liver and renal function (Figure S4B), a clinically relevant outcome as it mirrors CDPP-associated renal toxicity in cancer patients administered concomitant rituximab (αCD20 mAb). Due to its reduced nephrotoxicity, we instead evaluated carboplatin (CBDCA) as an alternative alkylating-type cytotoxic agent that also had no significant effect on tumor growth alone, but significantly slowed tumor growth when combined with αCD20 mAb throughout duration of the CTX cycle (Figure 4A), without evidence of toxicity or morbidity (Figure S4B), thus achieving a more favorable outcome.

To determine whether enhanced response to CTX was restricted to platinum-based agents, we next evaluated the microtubule polymer stabilizer paclitaxel (PTX) in combination with αCD20 mAb and similarly found significantly slowed SCC growth during the treatment cycle (Figure 4B), associated with decreased serum IgG (Figure S4C). Histological evaluation of tumors from combinatorial-treated mice revealed reduced malignant keratinocyte proliferation that was paralleled by increased cell death (cleaved caspase-3 positivity; Figure 4C). We also note a reduction in vascular density (CD31+ vessels;
Infiltration of CD8+ T lymphocytes within tumors from as assessed by flow cytometry (left) and IHC (right). Unless otherwise indicated, statistical significance was determined via an unpaired t test, with *p < 0.05 and **p < 0.01.

Figure 3. B Cell-Deficient Mice Limit SCC Tumor Growth
(A and B) Growth of (A) PDSC5 (clone 6; PDSC5.6) and (B) WDSC1 tumor cells injected orthotopically into syngeneic JH+/+ (red), JH+/− (blue), and JH−/− (green) mice. * denotes statistically significant differences in tumor growth between JH+/+ and JH−/− mice. One of two representative experiments is shown and depicted as mean ± SEM (‡10 mice per group). Representative H&E sections are shown to the right. Scale bars, 50 µm.

(C) Growth of PDSC5.6-derived tumors in syngeneic mice treated with 2-week interval dosing of αCD20 (red) or αRW (blue) mAb either at the time of PDSC5.6 tumor cell inoculation (day 0), or alternatively in mice that received αCD20 mAb (green) following appearance of visible tumors (day 12). * indicates statistically significant differences between tumor growth in mice receiving αCD20 at day 12 compared to αCD20 or αRW at day 0. One of two representative experiments is shown depicted as mean ± SEM (‡10 mice per group).

(D) Infiltration of CD8+ T lymphocytes within tumors from (C) as assessed by flow cytometry (left) and IHC (right). Unless otherwise indicated, statistical significance was determined via an unpaired t test, with *p < 0.05 and **p < 0.01. See also Figure S3.

Figure 4C; Figure S4D), although no apparent change in vascular leakage as measured by Evans blue assay (Figure S4D).

Given that αCD20 mAb improved responsiveness to PTX, we assessed the durability of tumor repression after one cycle of combined αCD20/PTX therapy and found that tumor regrowth was apparent within 10 days following cessation of PTX (Figure 4D). Because resistance to cytotoxic agents represents a major limitation of CTX, we evaluated a second cycle of αCD20/PTX therapy and found that tumors again responded to combined therapy, but again, that regrowth was evident following cessation of CTX (Figure 4D).

T Cell Infiltration in αCD20/PTX-Treated Tumors
To identify cellular mechanisms underlying slowing of tumor growth and increased efficacy of PTX in αCD20-treated mice, we evaluated leukocyte complexity of orthotopic SCCs by flow cytometry and found that SCCs responding to αCD20/PTX contained significantly increased infiltrates of both CD4+ and CD8+ T cells, as compared to tumors that regained growth kinetics following therapy cessation (Figure 4D). Increased CD8+ T cell infiltration in responding tumors from αCD20/PTX-treated mice was not unique to this experimental setting, as when we analyzed neoplastic skin from 4-month-old K14-HPV16/B cell-deficient, HK14-PV16/FcγRγ-deficient, and K14-HPV16 mice enrolled in the intervention trial with αCD20 mAbs (Figure 1), we similarly observed increased presence of CD8+ T cells across all experimental groups as compared to controls (Figure 4E). To reveal the functional significance of increased T cell infiltrates, CD4+ and CD8+ T cells were individually depleted from SCC-bearing αCD20/PTX-treated mice (Figure S5A), thus revealing that improved PTX responses in αCD20 mAb-treated mice were CD8+ T cell dependent (Figure 5A), but CD4+ T cell independent (Figure S5B). Moreover, depletion of CD8+ T cells reinstated the characteristic density of CD31+ vessels to growing tumors (Figure S5C).

To reveal molecular mediators regulating productive CD8+ T cell activity, we evaluated cytokine mRNA expression in SCCs of treated mice and found significantly increased levels of interferon α (IFNα), granzyme B (GzmB), and TNF-α, consistent with reduced development of vasculature in tumors from αCD20/PTX-treated mice (Figure 4C) and our previous results (Andreu et al., 2010).

Given these findings, we examined whether the improved PTX response was due to increased numbers of CD8+ T cells, or instead to improved functionality of infiltrating CD8+ T cells, by evaluating mRNA expression of SCC infiltrating CD8+ and CD4+ T cells isolated by fluorescence-activated cell sorting (FACS). Regardless of prior αCD20 treatment, T cells infiltrating SCCs had unchanged surface expression of activation markers CD69 and CD44 (Figure S5D), and they expressed similar levels of IFN-γ, TNF-α, and functional indicators of CD8+ T cell killing capability (e.g., GzmA, GzmB, Prf1) (Figure S5E).
Although changes to a subset of cells would have been masked by our grouped analysis, these results suggested the improved therapeutic response associated with αCD20/PTX combined therapy was due to reprogramming of the immune microenvironment to favor either survival or infiltration of CD8+ T cells that in turn enhanced tumor cell killing.
Figure 5. Combination αCD20 mAb Plus CTX Inhibits SCC Tumor Growth by CD8+ T Cell-Dependent Mechanisms

(A) Tumor growth of PDSC5.6-derived SCCs in mice treated with αCD20 mAb, or αCD8 (clone YTS169.4; 500 μg)-depleting mAb, alone or in combination with PTX, as depicted by treatment regimen. One of two representative experiments is shown and depicted as mean ± SEM. * indicates statistically significant differences in tumor growth between αCD20/PTX-treated mice compared to mice receiving αCD20 mAb alone (5–10 mice per group).

(B) mRNA expression of PDSC5.6 SCCs from PBS-perfused αCD20/PTX-treated mice compared to mice receiving αRW/PTX at day 45 of treatment regimen.

(C) Relative expression (Fold) of Møs.

(D) Tumor Volume (mm³) for αCD20/PTX and αCD20/PTX/CRC5i treated mice.

(legend continued on next page)
Macrophage Programming Regulates CD8+ T Cell Recruitment

Given our previous findings that macrophages are functionally reprogrammed to favor a more Th1-type (classically activated or “M1-type”) inflammatory state in K14-HPV16 mice lacking either B cells or FcγRs (Andreu et al., 2010), we postulated that αCD20 mAb therapy was similarly reprogramming macrophages in SCCs of treated mice and that a macrophage-dependent mechanism differentially regulated CD8+ T cell infiltration. To investigate this hypothesis, we purified splenic CD8+ T cells (Figure S5F) and evaluated their chemotactic response to conditioned medium derived from FACS-sorted CD11b+Ly6C-Ly6G+F4/80+MHCII+ macrophages isolated from SCCs of αCD20/PTX versus αRW/PTX-treated mice (Figure S5G) and revealed a significant increase in CD8+ T cell recruitment in response to conditioned medium from αCD20/PTX-derived macrophages (Figure 5C). mRNA expression analysis of CD11b+Gr1-CD11c-F4/80+MHCII+ macrophages isolated from SCCs of αCD20/PTX-treated versus control mice revealed increased mRNA expression of several chemokines variably implicated in leukocyte recruitment, including Ccl2, Ccl3, Ccl5, Ccl7, and Ccl9 (Figure 5D), but no significant changes in other genes associated with macrophage repolarization, including Il1b, Il6, Il10, Il12a, Cd163, Msr1, Arg1, or Ym1 (data not shown). Splenic CD8+ T cells expressed CCR5 (binds CCL3, CCL4, and CCL5) and CXCR3 (binds CXCL10, CXCL11, and CXCL12) (Figure S5H), both of which have been linked to robust antitumor responses (González-Martín et al., 2011; Hong et al., 2011). Thus, we evaluated the effect of CCR5 and CXCR3 blockade on CD8+ T cell chemotaxis ex vivo and found that an αCCR5-blocking mAb alone abated CD8+ T cell chemotaxis to levels observed with macrophages isolated from SCCs of control αRW/PTX-treated mice (Figure 5E). Importantly, limiting in vivo tumor infiltration of macrophages with a neutralizing mAb to colony-stimulating factor 1 (αCSF1) (Figure S5I) blocked the combinatorial effect of αCD20/PTX treatment (Figure 5F) and restored the density of CD31+ vessels in SCCs to characteristic levels (Figure S5J). The combinatorial effect of αCD20/PTX treatment was similarly reversed by depletion of CD8+ T cells and also by use of the CCR5 inhibitor maraviroc (Figure S5F), collectively indicating that response to CTX in SCCs is regulated by CCR5-positive CD8+ T cells responding to macrophages programmed by humoral immunity (Figure 6). In support of a central role for CCL5/CCR5 in mediating a cytotoxic T cell response in SCC patients, we found a significant correlation between expression of CCL5 and expression of PRF1, GZMA, GZMB, and CD69 (Figure S5K) in human HNSCC (Ginos et al., 2004).

DISCUSSION

Herein, we provide evidence that therapeutic strategies aimed at depleting B cells and/or dampening humoral immunity represent tractable targets for anticancer therapy in SCC. In preclinical prevention and intervention trials, treatment of K14-HPV16 transgenic mice with B cell-depleting αCD20 mAbs or a Syk inhibitor as monotherapy prevented neoplastic progression to the dysplastic/carcinoma in situ state. Although SCC growth was significantly slowed in either B cell- or FcγR-deficient mice (Andreu et al., 2010), treatment of syngeneic mice bearing preexistent orthotopic SCCs was without consequence following αCD20 mAb monotherapy. However, when αCD20 mAb was delivered in combination with CTX (CDPP, CBDDA, and PTX), SCC growth was significantly slowed, accompanied by reduced tumor vascular density and increased T cell infiltration, effects not achieved by administration of CTX alone. Improved SCC response to CTX in αCD20 mAb-treated mice was dependent on presence of “reprogrammed” macrophages producing CCR5 ligands, because depletion of either macrophages or CD8+ T cells restored SCC growth kinetics and vascular density to characteristic levels. Together, these data indicate that myeloid-based pathways regulated by humoral immunity limit SCC responses to CTX not only by fostering tumor angiogenesis, but also by impairing CD8+ T cell infiltration into tumors. Immune microenvironments in solid tumors can therefore be effectively reprogrammed to elicit productive antitumor immune responses that bolster response to cytotoxic therapy, provided that specific protumoral immune pathways can be identified and therapeutically targeted.

Treatment of solid tumors with CTX, although often useful for palliation or prolonging life in the setting of advanced disease, remains limited, with survival benefit often measured in months for some tumor types. Having an adjunctive therapeutic option to reverse or minimize chemoresistance, or to provide additive benefit through alternate mechanisms (immunomodulation), represents an attractive therapeutic strategy. Recent approval of ipilimumab, an anti-CTLA4 mAb for use in malignant melanoma (Hodi et al., 2010), and sipuleucil-T, a dendritic cell vaccine that prolongs survival but not disease-free survival in...
hormone-refractory prostate cancer (Kantoff et al., 2010; Small et al., 2006), engenders not only support for immunotherapy in general, but also the concept that immune responses to cancer can be redirected for therapeutic gain. Although neither ipilimumab nor sipeucil-T is currently approved for use in conjunction with CTX, it is intriguing to speculate that their efficacy would be improved if administered following CTX, or in combination with therapies that blunt protumor immunity while also favoring an antitumor immune microenvironment. Results presented herein reveal that these types of responses can indeed be generated by combining αCD20 mAb with CTX, similarly to that achieved by delivery of CSF1 antagonists with CTX in mammary carcinomas (DeNardo et al., 2011). Although both modalities slow tumor growth dependent on CD8+ T cells, these improvements are achieved by distinct molecular mechanisms resulting from lymphoid-based regulation of myeloid cell programming. These distinctions may reflect organ-specific mechanisms governing immune response, or nuances of the oncogenic drivers of solid tumor development.

Clinically, vulva and oropharyngeal malignancies are typically of a high-risk HPV viral etiology (Chaturvedi, 2010); thus, K14-HPV16 mice phenocopy neoplastic progression in these tissues and likely recapitulate a protumorigenic role for B cells and/or humoral immunity in these locales. This assertion is consistent with results from screening a diverse assortment of human solid tumors for evidence of B cell infiltration, i.e., CD20 and/or Ig mRNA expression, wherein vulva and HNSCCs contained significantly increased levels of CD20 and Ig mRNA, consistent with histological evaluation of B cells in tumor tissue of these cancers as well as in human cutaneous SCCs. Several other human tumor types exhibited significant increases in CD20 and/or Ig mRNA as compared to corresponding normal tissue. B cell-deficient mice have previously been reported to also resist growth of a range of syngeneic tumors, including thymoma, colon, and mammary (Barbera-Guillen et al., 2000; Inoue et al., 2006; Shah et al., 2005; Tadmor et al., 2011), but in most instances these studies used nonorthotopic subcutaneous implantation. In several of these models, the protumorigenic role of B cells related to suppression of CD8+ T cell responses either directly through IL-10 (Inoue et al., 2006; Schioppa et al., 2011; Wong et al., 2010) or IL-15 (Chapoval et al., 1998), or indirectly through TGF-β and generation of regulatory T cells (Ölkahndu et al., 2011; Tadmor et al., 2011). Whereas our previous findings indicated a role for Igs and CICs in mediating these effects (Andreu et al., 2010; de Visser et al., 2005), in other tumor models, adoptive transfer of B lymphocytes, but not serum, restored tumor growth accompanied by reduced Th1 cytokines and CTL responses, suggestive of antibody-independent mechanisms (Ammirante et al., 2010; Shah et al., 2005). Because B cells infiltrate human SCCs, unlike what has been observed in murine models of HPV16-induced SCCs (Andreu et al., 2010; de Visser et al., 2005) and chemical carcinogenesis-induced SCCs (Schioppa et al., 2011), we cannot rule out a potential role in human cancers for other B/plasma cell-derived factors such as granulocyte-macrophage-CSF (Rauch et al., 2012) or lymphotoxin (Moseman et al., 2012), as has been described for growth of subcutaneous androgen-independent metastatic prostate cancer cells (Ammirante et al., 2010).

B cell depletion as an adjunct to CTX in solid tumors should be relatively straightforward to address clinically. RituXimab is already an approved drug for B cell malignancies (McLaughlin et al., 1998), with no increased susceptibility to infection in patients with adult acute lymphoblastic leukemia, rheumatoid arthritis, or non-Hodgkin’s lymphoma (Silverman, 2006). This is likely due to the fact that plasma cells are not depleted by αCD20 mAb therapy. We observed “normalized” IgG levels in tumor-bearing mice following αCD20 mAb therapy; thus, targeting pathological production of IgG through depletion of short-lived autoreactive cells without affecting immunity derived from plasma cells could be achieved in solid tumors, similar to that described for arthritis (Huang et al., 2010) and peripheral nervous system autoimmunity (Maurer et al., 2012). Although rituximab has few cumulative side effects and has been combined safely with many CTXs (Gökbüget and Hoelzer, 2006), it should be noted that rituximab has been reported to increase risk of some solid tumors in patients with lymphoma also treated with high-dose CTX and stem cell autografts (Tarella et al., 2011). Alternatively, the clinical success of ibrutinib, an irreversible small-molecule inhibitor of BTK (expressed by both B cells and myeloid cell subsets), engenders support for the notion that targeting protumoral B cells and humoral immune-activated pathways may improve overall survival in patients with tumors regulated by these pathways, when administered in combination with standard-of-care CTX.
Although studies presented herein identify SCCs as potentially benefitting from \( \alpha \)CD20 mAb/CTX, the clinical relevance of \( \alpha \)CD20 mAb may not be limited to just these solid tumors. Growth of experimental lung adenocarcinoma is reduced in B cell-deficient mice, with an improved CTX response observed upon coadministration with IL-15, a Th1 cytokine with IL-2-like antitumor bioactivities (Chapoval et al., 1998). Moreover, in a mouse model of melanoma, B cell deficiency provided a therapeutically advantageous to a melanoma vaccine where enhanced tumor protection in the absence of B cells was associated with increased magnitude and longevity of specific cellular immune responses provoked by vaccination (Perricone et al., 2004). We also observed a striking increase in Ig expression in human pancreatic ductal adenocarcinoma samples and are currently evaluating whether this signature translates into a functional role in murine pancreas cancer models. Notably, a limited clinical study of advanced colon cancer patients treated with rituximab resulted in reduced numbers of CD21-hyperpositive lymphocytes associated with apparent 50% reduction in tumor burden with no ill effects due to therapy (Barbera-Guillem et al., 2000). Because human SCCs appear to be enriched with tumor-promoting B cells, we propose these as tractable cancers in which to examine efficacy of \( \alpha \)CD20 mAb, or other antagonists blocking protumoral B cell/humoral immunity programs, such as Syk or BTK inhibitors, in combination with CTX.

**EXPERIMENTAL PROCEDURES**

**Microarray Data Normalization and Integration**

Microarray data reflecting CD20 and Ig mRNA in human tumor samples were queried from a commercially available data set (BioExpress System, Gene Logic) originally generated on the Human Genome U133 Plus 2.0 Array (Affymetrix) and normalized by standard robust multi-chip average procedure. A single probe set of the highest variance among samples was chosen to represent CD20 (228592_at; MS4A1) and Ig (211430_s_at; IGHG1, IGH2, IGHV4-31, IGHM), respectively. To ensure data consistency, results from additional probe sets were compared to a single probe set. Median value was used to calculate fold change of expression in tumor tissue compared to normal tissue. Statistical analyses were performed using Wilcoxon rank-sum test to compare mRNA expression levels to their corresponding normal tissue controls.

**Immunohistochemistry**

Staining on human tissue sections was performed as described previously (Ruffell et al., 2012). De-identified human tissue was received from the University of California, San Francisco (UCSF) Department of Pathology under approval from the UCSF Committee on Human Research (0028810), and the Oregon Health and Science University (OHSU) Department of Dermatology Molecular Profiling Resource (institutional review board [IRB] #809), with patient consent forms obtained at the time of tissue acquisition. The use of samples occurred under "exempt category 4" for individuals receiving de-identified biological specimens.

**Animal Husbandry and In Vivo Studies**

Generation and characterization of K14-HPV16 and JH \(^{-/-}\) mice have been described previously (Andreu et al., 2010). Briefly, K14-HPV16 transgenic mice represent a well-characterized model of multistage epithelial carcinogenesis where HPV16 early region genes are expressed under control of a K14 promoter, i.e., K14-HPV16 mice (Arbet et al., 1994; Coussens et al., 1996, 1999,2000; Daniel et al., 2003; de Visser et al., 2004; Rhee et al., 2004; van Kempen et al., 2002). By 1 month of age, K14-HPV16 mice develop hyperplastic lesions (hyperplasias) throughout skin. Between 3 and 6 months of age, these hyperplasias progress into 100% penetrant focal dysplasias and are predisposed to progress into multiple histlogic grades of SCC in ~50% of mice on the FVB/n strain background, 30% of which metastasize to regional lymph nodes. Angiogenic vasculature is first evident in hyperplasias, development of which is linked to infiltration of innate immune cells (de Visser et al., 2004, 2005; van Kempen et al., 2002). All experiments with mice complied with National Institutes of Health guidelines and were approved by the UCSF Institutional Animal Care and Use Committee.

\( \alpha \)CD20 mAb (clone 5D2, provided by Genentech) was generated by immunizing CD20-deficient mice with a murine pre-B cell line (300,19) transfected with murine CD20. CD2Bs encoding heavy and light chain were cloned from hybridomas and further used for transfection and antibody production in Chinese hamster ovary cells. Ragweed-specific mouse IgG2a (\( \alpha \)RW mAb) was used as an isotype control. K14-HPV16 mice received \( \alpha \)CD20 (200 \( \mu \)g) or \( \alpha \)RW (200 \( \mu \)g) mAb intraperitoneally (i.p.) at 2-week intervals commencing at 1 or 3 months of age. Mice bearing syngeneic orthotopic tumors received \( \alpha \)CD20 mAb (200 \( \mu \)g) or \( \alpha \)RIW mAb (200 \( \mu \)g) either at the time of tumor cell inoculation (day 0) or following appearance of palpable transplantable tumors (e.g., day 12) at 2-week intervals for a total of three treatments. K14-HPV16/FcR\(^{\gamma}\) (\( \geq 18 \) mice per cohort) and K14-HPV16/FcR\(^{\gamma}\) (\( \geq 10 \) mice per cohort) mice were fed chow containing orally soluble fostamatinib (R788) at 2.9 g of fostamatinib per kg of chow, as compared to control chow (AIN-76A) (Rigel Pharmaceuticals) ad libitum beginning at 1 month of age and continuing for a total of 12 weeks. Formulated chow was prepared by Research Diets. R406 (R940406) is the active metabolite of fostamatinib that acts as an ATP-competitive inhibitor (K\(_i\) = 30 \( \mu \)M), thus selectively inhibiting Syk kinase activity as assessed using a large panel of Syk-dependent and -independent cell-based assays (Braasch et al., 2008). Plasma R406 levels were monitored for 48, 51, 54, 57, and 58 hr, revealing peak plasma levels at 558 ng/ml in male FVB/n mice and peak levels in female FVB/n mice at 118.9 ng/ml (data not shown). Thus, using 2.0 mg/g (10-fold higher than the tested dose), Syk kinase activity in female FVB/n mice was inhibited in vivo and was monitored as a function of plasma R406 levels and Syk kinase activity in peripheral blood leukocytes.

**Orthotopic Tumor Transplantation**

PDSC5 and WDSC cells (0.5 \( \times \) 10\(^6\) cells) were suspended in 100 \( \mu \)l of baseline membrane extract Matrigel (BD Pharmingen) in PBS (1:1) and inoculated orthotopically into back skin of 7-week-old female FVB/n mice. Transplantable tumors were measured at 2-day intervals using a digital caliper, and tumor volume was calculated using the equation \( V (\text{mm}^3) = \frac{a \times b^2}{2} \), where \( a \) is the largest diameter and \( b \) is smallest diameter. To assess effects of PTX (12 mg/kg: Novaplus), CDPP (10 mg/kg: Hospira), and CBDDCA (50 mg/kg: APP Pharmaceuticals) on tumor growth, tumor-bearing mice were pretreated with \( \alpha \)CD20 mAb or \( \alpha \)RW mAb as described above. Chemotherapeutic agents were injected intravenously at 4-day intervals 1 week following administration of the second dose of \( \alpha \)CD20 or \( \alpha \)RW mAb for a total of three treatments. Mice were sacrificed 4 days following the last chemotherapeutic dose. For tumor regression studies, mice were treated with \( \alpha \)CD20 mAb/PTX following growth of transplantable tumors. Mice received PTX at a 4-day interval for a total of three treatments. For in vivo depletion studies, \( \alpha \)CD4 (GK1.5) and \( \alpha \)CD8 (YTS169.4) mAbs were administered i.p. at 500 \( \mu \)g on day 4 following initial treatment with \( \alpha \)CD20 mAb at a 5-day interval, whereas \( \alpha \)CSF1 (5A1) antibodies (all from Bio X Cell) were administered i.p. at 1,000 \( \mu \)g 4 days prior to the first chemotherapeutic dose, with subsequent doses of 500 \( \mu \)g every 4 days. Clinical grade maraviroc was dissolved at 300 mg/ml in drinking water for ad libitum dosing (Ochoa-Caldero et al., 2013).

**Statistical Analyses**

Statistical analyses were performed using Prism version 4 and/or InStat version 3.0a for Macintosh (both GraphPad). Specific tests included Mann-Whitney (unpaired, nonparametric, two-tailed), unpaired t test, and Wilcoxon rank-sum and are identified in the respective figures. p Values < 0.05 were considered statistically significant, with *p < 0.05, **p < 0.01, and ***p < 0.001 unless otherwise indicated.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes Supplemental Experimental Procedures and five figures and can be found with this article online at http://dx.doi.org/10.1016/j.ccr.2014.04.026.
AUTHOR CONTRIBUTIONS

N.I.A. and B.R. contributed equally to this work through the design and execution of experiments, analysis of data, and preparation of the manuscript.

ACKNOWLEDGMENTS

We thank the Knight Cancer Center Flow Cytometry shared resource; Genentech for providing sCD20 and sRW mAbs; and members of the L.M.C. lab for critical discussion. We also thank the OHSU Department of Dermatology Molecular Profiling Resource (IRB #809) and the OHSU Knight Cancer Institute (NCI P30CA069533) for support of other Shared Core Resources used for studies herein. This work was supported by the American Association for Cancer Research and a NIH postdoctoral training grant in Molecular & Cellular Mechanisms in Cancer to N.I.A. (T32 CA108462); a Department of Defense Breast Cancer Research Program Fellowship to B.R. (WB1XWH-09-1-0543); NIH/NCI training grants to T.R.M. (T32CA106195) and A.J.G. (T32AI079803-04); and grants from the NIH/NCI (R01 CA130980, R01 CA140943, R01 CA155331, U54 CA163123), a DOD BCRP Era of Hope Scholar Expansion Award (WB1XWH-08-PMRP-IRIA), the Susan B Komen Foundation (KG111084 and KG110560), and the Breast Cancer Research Foundation to Rigel Pharmaceuticals, but no employees of Rigel had any involvement in research and manuscript preparation. Grants from the NIH (CA109686, CA140185, CA155873, CA155872, CA140943, CA130980, CA108462, CA155331, and AI079803), and the Breast Cancer Research Foundation to the L.M.C. lab funded the studies herein. This work was supported by the American Association for Cancer Research and a NIH postdoctoral training grant in Molecular & Cellular Mechanisms in Cancer to N.I.A. (T32 CA108462); a Department of Defense Breast Cancer Research Program Fellowship to B.R. (WB1XWH-09-1-0543); NIH/NCI training grants to T.R.M. (T32CA106195) and A.J.G. (T32AI079803-04); and grants from the NIH/NCI (R01 CA130980, R01 CA140943, R01 CA155331, U54 CA163123), a DOD BCRP Era of Hope Scholar Expansion Award (WB1XWH-08-PMRP-IRIA), the Susan B Komen Foundation (KG111084 and KG110560), and the Breast Cancer Research Foundation to L.M.C. Y.L., Q.G., Y.M., and B.I. are employees of Genentech. Work with fostamatinib disodium was performed under a sponsored research agreement with Rigel Pharmaceuticals, but no employees of Rigel had any involvement in data collection, analysis, or interpretation.

Received: December 8, 2013
Revised: February 13, 2014
Accepted: April 30, 2014
Published: June 5, 2014

REFERENCES


Cancer Cell

B Cells as a Therapeutic Target in SCC


